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The use of somatic cells to generate induced-pluripotent stem cells (iPSCs), which have gene characteristic resembling those of
humanembryonicstemcells(hESCs),hasopenedupanewavenuetoproducepatient-speciﬁcstemcellsforregenerativemedicine.
MicroRNAs (miRNAs) have gained much attention over the past few years due to their pivotal role in many biological activites,
including metabolism, host immunity, and cancer. Soon after the discovery of embryonic-stem-cell- (ESC-) speciﬁc miRNAs,
researchers began to investigate their functions in embryonic development and diﬀerentiation, as well as their potential roles in
somatic cell reprogramming (SCR). Several approaches for ESC-speciﬁc miRNA-mediated reprogramming have been developed
using cancer and somatic cells to generate ESC-like cells with similarity to iPSCs and/or hESCs. However, the use of virus-
integration to introduce reprogramming factors limits future clinical applications. This paper discusses the possible underlying
mechanism for miRNA-mediated somatic cell reprogramming and the approaches used by diﬀerent groups to induce iPSCs with
miRNAs.
1.Introduction
In the 1980s, the ﬁrst mouse embryonic stem cell line, which
displayed both the capability for unlimited proliferation and
thepluripotencyandcapacitytodiﬀerentiateintothreegerm
layers, was established, and since then, embryonic stem cells
have shown great promise for advancing the ﬁelds of drug
discovery, disease modeling, and regenerative medicine.
It was believed that cells diﬀerentiated in a unidirectional
manner until the invention of somatic cell nuclear transfer
(SCNT) [1]. This technique replaces the nuclei of oocytes
with those of somatic cells, resulting in the reversal of the
fused cells from a diﬀerentiated to pluripotent status. Subse-
quently, many species of mammalian cells have been success-
fully cloned, including the famous cloned sheep Dolly [2].
However, this approach raises problems, such as the ethical
concerns regarding the use of embryos and the technical
challenges and low success rate associated with this method.
In 2006, Takahashi and Yamanaka successfully generated
induced-pluripotent stem cells (iPSCs) with a novel ap-
proach using the viral integration of the four transcription
factors, Oct4, Sox2, Kl4, and c-Myc [3]. This revolutionary
approach has demonstrated the feasibility of using somatic
cells to generate iPSCs. Patient-speciﬁc iPSCs can be derived
from cells of the same patient, thereby avoiding the immune
rejection that occurs with SCNT or human embryonic stem
cells (hESCs). More importantly, use of somatic cells as
the starting material circumvents the ethical issues associat-
ed with the use of human embryos. Subsequently, many
iPSCs have been generated from various types of somatic
cells, including keratinocytes, neuronal stem cells, and ﬁbro-
blasts, among others [3–6]. These iPSCs display gene expres-
sion patterns, cell morphology, and the capacity of forming
teratoma in vivo similar to those of hESCs [3, 6]. Neverthe-
less, the use of retroviral delivery hinders its application in
clinical therapy because integration of viral genes into the
iPSC genome may cause instability that leads to undesired
mutations [7]. In addition, studies have shown that the
ectopic expression of c-Myc, one of the original four tran-
scription factors, correlates with increased tumorigenicity
and further raises questions about the therapeutic potential
of iPSC generated in this manner [8]. Although successful
reprogramming has been reported using only 2 Yamanaka
factors in the absence of c-Myc, this approach results in2 Stem Cells International
greatly decreased eﬃciency [9]. In addition, synthetic mod-
iﬁed mRNAs have been used to replace viral delivery for ele-
vating expression of the four Yamanaka factors, and while
these studies demonstrated the eﬃcient reprogramming of
cells in the absence of retrovirus, ectopic c-Myc was still pre-
sent [10, 11].
In 2004, Suh and colleagues identiﬁed a set of embryonic
stem cell-speciﬁc microRNAs (miRNAs), [12] which have
subsequently been found to contribute to embryo develop-
ment [13–15]. In fact, deﬁciency in theses miRNAs can cause
detrimental defects in cell proliferation and diﬀerentiation
[16, 17]. Among the highly expressed ESC-speciﬁc miRNAs,
miR-302/367 is highly expressed in early embryonic devel-
opment and then rapidly declines after diﬀerentiation [12,
13]. This information prompted several laboratories to in-
vestigatetheroleofmiR-302/367inreprogramming[18–20].
Numerous miRNA-mediated iPSC lines have been subse-
quentlydevelopedwitheithermiR-302/367oracombination
of miR-302 and other miRNAs from mouse ﬁbroblast, hu-
man dermal ﬁbroblast, and human skin cancer cells [21, 22].
As this approach avoids the use of oncogene c-Myc, the
possibilityexiststhatmiRNA-reprogrammediPSCswouldbe
more suitable for human use.
2.ProposedMechanismof
miR-302/367-MediatedReprogramming
Currently, the mechanism by which somatic cells generate
iPSCsremainsunclear.Maternalmaterialsratherthandown-
stream transcription factors regulate the maintenance and
renewal of fertilized oocytes [23]. A large portion of RNAs
in mouse oocytes are transcribed from the maternal gen-
ome, and maternal miRNAs present in the oocyte rapidly
decline during the oocyte-zygote transition. Therefore, it is
reasonable to assume that these maternal miRNAs inhibit
thedevelopmentalsignalformaintainingpluripotencyinthe
early embryonic stage through an RNAi eﬀect. This, in com-
bination with the observation of high miR-302/367 expres-
sion in the early embryo followed by a rapid decrease upon
diﬀerentiation, strongly suggests that miR-302/367 serves as
upstream pluripotency regulator to modulate the expression
of Oct4, Sox2, Nanog, and other embryonic transcription
factors. Given that miRNA can target several to hundreds of
genes, the inhibition of multiple factors and pathways likely
initiates miR-302/367 reprogramming.
miR-302/367 targets multiple epigenetic factors, leading
to global demethylation. Global DNA demethylation occurs
at the promoter binding site of several ESC-speciﬁc trans-
cription factors during the 1–8 cell stages of early zygotes,
resulting in preservation of imprinting. The same mecha-
nism very likely happens during somatic cell reprogramming
(SCR). MiR-302 silences lysine-speciﬁc histone demethylases
1 and 2 (AOF1 and AOF2) and methyl-CpG-binding pro-
teins 1 and 2 (MECP1-p66 and MECP2). DNA methyltrans-
ferase 1 (DNMT1), an essential regulator in DNA methy-
lation, is then silenced in response to the downregulation
of AOF2, leading to genomewide demethylation and conse-
quently coactivation of pluripotency-promoting genes [20,
24]. Indeed, silencing AOF2 enhanced global demethylation
during reprogramming of human hair follicle cells by miR-
302s [20].
miR-302/367 also directly targets NR2F2, a member of
the nuclear orphan receptor family of transcriptional factors
and a negative regulator of Oct4 [25]. In hESCs, NR2F2
expression begins with diﬀerentiation and conversely corre-
lates with the expression of Oct4 and miR-302/367. Studies
have also shown that Oct4, Nanog, and Sox2 bind to the pro-
moter regions of miR-302/367 and increase its expression
level [26]. Taken together, miR-302/367 expression induces
global demethylation and suppresses NR2F2, two events that
indirectly activate Oct4 expression, which in turn elevates
miR-302/367 levels. This reciprocal cycle increases cellular
levelsofmiR-302/367andOct4,whichleadstotheco-activa-
tion of other transcription regulators, such as Sox2 and
Nanog. Studies from Lin and colleagues showed that over-
expression of mir-302/367 (approximately 1.1- to 1.3-fold as
comparedwithnormalhESCs)leadstoglobaldemethylation
and coexpression of Oct4, Sox-2, and Nanog in human
iPSCs [20, 27]. A similar study using RUES2 cells conﬁrmed
that transfection with miR-302 elevates Oct4 and Nanog ex-
pression [14].
Additional targets may include the transforming growth
factor beta receptor II (TGFBR2) and ras homolog gene fam-
ily member C (RHOC) genes. A recent study has reported
thatacombinationofmiR-302bandmiR-372downregulates
TGFBR2 and RHOC gene expression [19]. Furthermore, the
inhibition of these two molecules correlates with increased
eﬃciency of iPSC induction [19]. Evidence has shown that
mesenchymal-to-epithelial transition (MET) occurs during
theearlyreprogrammingprocessinmouseﬁbroblastsasare-
sult of blocking pro-epithelial-to-mesenchymal signals, such
as TGF-beta [28]. The same process may also occur during
reprogramming in human cells. We found that the miR-
302 may also target TGFBR2 and RHOC, supporting the
possibility that miR-302/367 has the same eﬀect on MET as
miR-302b/327. However, conﬁrmation of this hypothesis re-
quires further study.
miRNA-reprogrammed iPSCs display a decrease in
tumorigenecity as compared with the iPSCs generated by
conventional approaches [27], which is likely due to multiple
factors. For example, miRNA-mediated somatic cell repro-
gramming does not require enhanced expression of c-Myc;
therefore, no oncogene is involved in the process. Also, miR-
302/367 targets several cell cycle regulators. During miRNA-
mediated SCR, both cyclin E-CDK and cyclin D-CDK4/6
undergo downregulation. Consequently, this attenuates the
G1to Sphasetransition, resulting in decreasediPSCstumor-
igenicity. In addition, two tumor suppressor genes, p16Ink4a
and p14/19Arf, undergo upregulation through the silencing
of BMI1 (B lymphoma Mo-MLV insertion region 1 ho-
molog). Taken together, the cell cycle of microRNA-repro-
grammed iPSCs is highly regulated and resembles the early
m a m m a l i a nz y g o t e( 2 0t o2 4h o u r s )[ 27].
3. Different MicroRNA Approaches for SCR
In order to study the role of miRNAs in reprogramming as
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artiﬁcial expression vector that can both generate functional
mature miRNAs and maintain their expression in vitro and
in vivo. Previously, several vectors have been established that
use RNA polymerase III transcription activity to generate
stable miRNA expression [29–32]. These vectors, however,
have several drawbacks. First, the ubiquity of pol III makes
it is diﬃcult to target a speciﬁc population of cell types. Sec-
ond, transcription by RNA pol III requires U6 and H1 pro-
moters. Pol III activity could potentially generate the accu-
mulation of large RNA transcripts (>25bps), thereby pro-
ducing interferon cytotoxicity [33, 34]. A recombinant gene
expression system, mediated by RNA polymerase II and
based on the mechanism of miRNA biogenesis, has also been
developed [35–37]. The precise regulation of RNA splic-
ing and nonsense-mediated decay of pol-II-directed RNA
biogenesis ensures the degradation of excessive RNA accu-
mulation and alleviates potential toxicity caused by high
levels of long double-stranded RNAs [38, 39]. miRNAs
transcriptsarefrequentlylocatedinanintroninproximityto
the protein coding region; thus, this expression system uses
an artiﬁcial intron (SpRNAi) placed between two exons that,
together, encode a reporter, such as green or red ﬂuorescent
protein. Because the intronic miRNA of interest disrupts the
functional structure of the reporter gene, expression will not
occur without proper RNA splicing. Detection of the ﬂuo-
rescent signal provides a means to monitor the production
of this intronic miRNA. The artiﬁcial intron (SpRNAi) con-
sists of the following components: a 5 -splice site, a branch-
point domain, a polypyrimidine tract, and a 3 -splice site,
and the pre-miRNA insert is placed between the 5 -splice site
and branch-point domain. This system has been shown to
induce the RNAi eﬀect in LNCaP, HeLa, and HCN-A94-2
c e l l sa sw e l la si nm i c e[ 40, 41].
To date, viral transfection serves as the primary method
to introduce reprogramming factors, either Yamanaka fac-
tors or miRNAs, into cells due to its high eﬃciency of deli-
very. However, as mentioned previously, this may result in
the integration of exogenous genes into the host genome and
as such is not ideal for clinical trials. Many studies have been
conducted to ﬁnd alternatives with higher transduction eﬃ-
ciency. A recent study examined mature miRNAs rather
than vector-based delivery as a potential approach for SCR
[18]. The use of mature miRNA bypasses the DNA-based
plasmid and thus avoids any possible insertion of genes into
genome of targeted cells. Further, higher eﬃciency (0.1%)
has been achieved as compared with the retroviral delivery of
the Yamanaka factors (0.01∼0.04%). Although this method
seems promising, several problems remain. Depending on
the cell type and experimental conditions, SRC requires suf-
ﬁcientamountsofcellularmaturemiRNAsoverthecourseof
days to weeks. Thus, repeated transfections may be necessary
to maintain the appropriate levels over time. The need for
ample amounts of synthetic nucleotides may greatly increase
the cost for the large-scale production of iPSCs in a clinical
setting. Moreover, instead of the miR-302 family alone, it
has been argued that successful reprogramming by mature
miRNAs always requires the combination of miR-302s, miR-
200c, and miR-369, while several miRNA-mediated iPSC
lineshavebeengeneratedwithonlymiR-302ormiR-302/367
[20, 22].
4. Conclusions
Based on evidence of the successful establishment of iPSC
lines using a miRNA-mediated strategy, it seems that ESC-
speciﬁc miRNA, especially the miRNA-302/367 family, can
induce reprogramming events similar to those of Yamanaka
factors. The use of a miRNA expression vector, such as the
intronic miRNA expression system, provides a simple and
safe way to generate iPSCs due to the fact that no oncogene
is required for successful reprogramming and, in the case of
miR-302/367, only a single transcript is transfected rather
than the simultaneous transfection of multiple genes, whose
expression would be diﬃcult to consistently maintain in
iPSCs. In general, delivery of premade miRNAs provides a
fast and direct way to recapitulate miRNA-mediated RNAi
as compared to a vector-based approach. While its practi-
cality for large-scale production of patient-speciﬁc iPSCs re-
mainstobedetermined,thepotentialunderlyingmechanism
of miRNA-mediated reprogramming suggests that it may
represent an improved means to generate patient-speciﬁc
iPSCs, with better quality and safety for regenerative medi-
cine and transplantation therapy.
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